In 2020, the trial NCT04424966 enrolled participants with recurrent high-grade glioma with FGFR1 K656E or FGFR3 K650E mutations or FGFR3-TACC3 translocation (demonstrated by NGS sequencing, IHC and/or RT- PCR) for the clinical assessment of infigratinib [97]. This evidence concerns the gene FGFR3 and central nervous system cancer.